Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study-Reference-Cited by-同舟云学术

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

Published:2015-09-14 Issue:1 Volume:51 Page:51-57
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Van Den Neste E,Schmitz N,Mounier N,Gill D,Linch D,Trneny M,Milpied N,Radford J,Ketterer N,Shpilberg O,Dührsen U,Ma D,Brière J,Thieblemont C,Salles G,Moskowitz C H,Glass B,Gisselbrecht C

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2015213.pdf

Reference33 articles.

1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

2. Gisselbrecht C . Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? Hematology Am Soc Hematol Educ Program 2012; 2012: 410–416.

3. Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111: 537–543.

4. Karlin L, Coiffier B . Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions. Onco Targets Ther 2013; 6: 289–296.

5. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040–2045.

Cited by 231 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration;Cancer Medicine;2024-09

2. Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma;Journal of Blood Medicine;2024-09

3. CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis;Blood;2024-08-08

4. Diffuse large B-cell lymphoma and follicular lymphoma: problem state in Russia;Journal of Modern Oncology;2024-07-03

5. Zelluläre Therapien im Alter: Everything, everywhere, all at once?;InFo Hämatologie + Onkologie;2024-07